Potential biomarker found for ALS patients; Daiichi Sankyo exec talks biomarker challenges;

> Serum N-acetylaspartate could be a worthy biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, after it was found in significantly higher volumes in ALS patients. The study was published in the Archives of Neurology. Article

> Santa Clara, CA-based biotech NextBio has discovered a potential cancer biomarker in the so-called "gene desert" in the human genome. Release

> Dr. Catherine Larue has been named the executive vice president of biomarkers at GENFIT. Larue previously worked at Bio-Rad in R&D and business units, as well as the immunology department at Sanofi Diagnostics Pasteur. Announcement

And Finally... Dr. Robert Beckman, the executive director of clinical development oncology at Daiichi Sankyo, discussed the difficulties facing the biomarker market with Hanson Wade: the discussion highlighted that the main issues it faces are maximizing efficiency and managing their resources, whether it's the patient market or their finances. Daiichi Sankyo release

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.